NCT02551224View on ClinicalTrials.gov

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Pulmonary Disease, Chronic Obstructive (COPD)
Interventions
OTHER

Patient preference questionnaire

The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.

Trial Locations (10)

1900

Novartis Investigative Site, La Plata

7600

Novartis Investigative Site, Mar del Plata

C1426ABP

Novartis Investigative Site, CABA

B1602DQD

Novartis Investigative Site, Florida

B1602DOH

Novartis Investigative Site, Vicente López

B1842DID

Novartis Investigative Site, Buenos Aires

C1120AAC

Novartis Investigative Site, Buenos Aires

C1425AUA

Novartis Investigative Site, Buenos Aires

Unknown

Novartis Investigative Site, CABA

C1425FVH

Novartis Investigative Site, Ciudad Autonoma de Bs As

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY